medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 5

<< Back Next >>

Med Int Mex 2018; 34 (5)

Remission of metabolic syndrome with bariatric surgery

Escalante-García M, López-Rosales F, Hernández-Escalante VM, Martínez-Díaz G, Torres-Escalante JL, Castro-Sansores CJ

Language: Spanish
References: 24
Page: 678-682
PDF size: 363.58 Kb.


ABSTRACT

Objective: To determine the relief of comorbidities in patients undergoing bariatric surgery of metabolic syndrome in the Regional Hospital of High Specialty of the Yucatan Peninsula, Mexico.
Material and Method: A retrospective observational study was done from 2011 to 2014 in patients with a body mass index (BMI) ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities undergoing bariatric surgery. The diagnostic criteria of the metabolic syndrome were those of the International Diabetes Federation applied to the Mexican population.
Results: A total of 67 patients undergoing bariatric surgery (laparoscopic Roux-en-Y gastric bypass) were included in the study; 79% were women, the age range was 19- 55 years with an average of 36.5 ± 119.4 ± 20 kg. The average percentage of postoperative weight loss was 19.8%, 27.9% and 34.3% at 3, 6 and 12 months, respectively. The mean weight, BMI, systolic and dyastolic blood pressure, total cholesterol, LDL, HDL and glucose decreased significantly (p ‹ 0.001) one year after surgery. The percentages of remission were: metabolic syndrome, diabetes mellitus and low HDL-cholesterol: 100%, arterial hypertension: 94.1%, hypertriglyceridemia: 60.9%.
Conclusion: At twelve months, the remissions of metabolic syndrome, diabetes mellitus and low HDL were 100%, being greater than 60% in the other components of the metabolic syndrome.


REFERENCES

  1. Gutiérrez JP y col. Encuesta nacional de salud y nutrición 2012 resultados por entidad federativa. Yucatán. Resultados Nacionales Cuernavaca, México: Instituto Nacional de Salud Pública, 2012;1:112.

  2. Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab 1998;23:116-123.

  3. Pories WJ, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992;215:633-643.

  4. Pories WJ, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-352.

  5. Laferrère B. Diabetes remission after bariatric surgery: is it just the incretins? Doi: 10.1038/ijo.2011.143.

  6. Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Doi: 10.1016/j. numecd.2008.07.004.

  7. Bose M, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Doi: 10.1007/s11695-008-9696-3. Epub 2008 Sep 27.

  8. Kini S, Herron DM, Yanagisawa RT. Bariatric surgery for morbid obesity - a cure for metabolic syndrome? Med Clin North Am 2007;91:1255-71.

  9. Christou NV, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004;240:416-24.

  10. Kang JH, et al. Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. Doi: 10.1097/MD.0000000000008632.

  11. Chang S, et al. Bariatric surgery: an updated systematic review and metaanalysis, 2003-2012. Doi:10.1001/jamasurg. 2013.3654.

  12. Padwal R, et al. Bariatric surgery: a systematic review and network metaanalysis of randomized trials. Obes Rev Mar 28, 2011.

  13. Fouse T, et al. The socioeconomic impact of morbid obesity and factors affecting access to obesity surgery. Doi: 10.1016/j.suc.2016.03.002.

  14. Tello-Mendoza TA, et al. Comparación del estado metabólico antes y después de la cirugía bariátrica en pacientes del Centro Médico Nacional 20 de Noviembre. Rev Endoc y Nut 2009:107-114.

  15. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from: https://www.idf.org.

  16. Dixon JB, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316-3.

  17. Hinojosa MW, et al. Resolution of systemic hypertension after laparoscopic gastric bypass. J Gastrointest Surg 2009;13:793-7.

  18. Nugent C, et al. Metabolic syndrome after laparoscopic bariatric surgery. Obes Surg 2008 Oct;18(10):1278-86.

  19. Nassour I, et al. Metabolic syndrome remission after Rouxen- Y gastric bypass or sleeve gastrectomy. Diabetes Metab Syndr Obes 2017 Sep 20;10:393-402.

  20. Junior FCM, et al. Effects of weight loss induced by bariatric surgery on the prevalence of metabolic syndrome. Arq Bras Cardiol 2009;92(6):435-9.

  21. Molina-Ayala M y col. Características clínicas y bioquímicas de pacientes con obesidad extrema al ingreso y un año después de someterse a cirugía bariátrica. Rev Med Inst Mex Seguro Soc 2016;54 Suppl 2:S118-23.

  22. Ramírez-Avilés E, et al. Evolution of type 2 diabetes and carbohydrate intolerance following bariatric surgery in a Mexican mestizo population. Cir Cir 2017;85(2):135-42.

  23. Oller I y col. Gastrectomia vertical laparoscópica calibrada con 50F:Efectos ponderales y metabólicos a medio plazo. BMI 2014;42:179-85.

  24. Schiavon CA, et al. Effects of bariatric surgery in obese patients with hypertension: The GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Doi:10.1161/CIRCULATIONAHA.117.032130. [Epub ahead of print]




2020     |     www.medigraphic.com